New combo aims to tame CAR T-Cell side effects in leukemia
NCT ID NCT05993949
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests whether adding pulses of the cancer drug dasatinib to standard CAR T-cell therapy (brexucabtagene autoleucel) is feasible and safe for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Eight participants receive dasatinib on a weekly 3-day schedule for up to 3 months after the CAR T-cell infusion. The goal is to see if this approach can reduce side effects without compromising the treatment's effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brexucabtagene autoleucel (CAR T-cell therapy) plus dasatinib (a cancer drug)
- What this could lead to
- If successful, this combination could help control leukemia by reducing side effects of CAR T-cell therapy, making treatment safer and more tolerable.
- What could go wrong
- This is a very early, small phase 1 trial with only 8 participants, so results may not apply broadly. The drug dasatinib also has its own risks, including potential side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University
Palo Alto, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot
- Double-Pronged immune cells take aim at stubborn blood cancers